Fermotein Does Not Exert Genotoxic Effects in Bacterial Reverse Mutation and in Vitro Mammalian Cell Micronucleus Tests
European Journal of Nutrition & Food Safety,
Aim: Fermotein is an innovative single-cell protein obtained from fermentation of the filamentous fungus Rhizomucor pusillus. Like other filamentous fungi, a lack of information on this species exists to assess its safety for human consumption. The capability to induce gene mutations or structural and numerical chromosomal aberrations of this fungus and derived products has never been studied before. The objective of the current study was to investigate the genotoxic effects of Fermotein using a bacterial reverse mutation test and an in vitro mammalian cell micronucleus test.
Methodology: The bacterial reverse mutation test and in vitro mammalian cell micronucleus test were performed in accordance with GLP and concurrent OECD guidelines. Dose-range finding tests were used to select appropriate doses of Fermotein Dry. The highest doses in the genotoxicity experiments were determined by the solubility of the mycoprotein.
Results: The bacterial reverse mutation test and in vitro mammalian cell micronucleus test were performed in accordance with GLP and concurrent OECD guidelines. Dose-range finding tests were used to select appropriate doses of Fermotein Dry. The highest doses in the genotoxicity experiments were determined by the solubility of the mycoprotein.
Conclusion: No safety concerns regarding genotoxicity were identified for Fermotein and no further in vivo genotoxicity testing is required. Information from the current study contributes to the body of evidence for a novel food authorisation of Fermotein in the EU and a GRAS notification in the US.
- Single-cell protein
- filamentous fungi
- Rhizomucor pusillus
- genotoxicity; bacterial reverse mutation (Ames) test
- in vitro mammalian cell micronucleus test
How to Cite
Ritala A, Häkkinen ST, Toivari M, Wiebe MG. Single Cell Protein - State-of-the-Art, Industrial Landscape and Patents 2001–2016. Front Microbiol. 2017; 8(2009).
European Commission. Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) No 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) No 258/97 of the European Parliament and of the Council and Commission Regulation (EC) No 1852/2001. Official Journal of the European Union. 2015;327:1–22.
U.S. Food and Drug Administration. Generally Recognized as Safe (GRAS); 2020.
Accessed 16 October 2020.
European Food Safety Authority. Introduction of a qualified presumption of safety (QPS) approach for assessment of selected microorganisms referred to EFSA Opinion of the Scientific Committee. EFSA J. 2007;5(12):587.
EFSA panel on biological hazards. Scientific opinion on the maintenance of the list of QPS microorganisms intentionally added to food or feed (2009 update). EFSA J. 2009;7(12):1431.
EFSA Panel on biological hazards. Scientific opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2010 update). EFSA J. 2010;8(12):1944.
Van der Spiegel M, Van den Driessche JJ, Leune E, Pařenicová L & De Laat W. Safety evaluation of Fermotein: Allergenicity, mycotoxin production, biochemical analyses and microbiology of a fungal single-cell protein product. European Journal of Nutrition & Food Safety. 2020;12(10):146-155.
EFSA Scientific Committee. Scientific Opinion on genotoxicity testing strategies applicable to food and feed safety assessment. EFSA J. 2011;9.9:2379.
Cimino MC. Comparative overview of current international strategies and guidelines for genetic toxicology testing for regulatory purposes. Environ. Mol. Mutagen. 2006;47:362-390.
OECD. Test No. 471: Bacterial Reverse Mutation Test, OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing, Paris; 2020.
European Commission. Council Regulation (EC) No 440/2008 of 30 May 2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH). Official Journal of the European Union. 2008;142: 1-739.
International conference on harmon- isation, harmonised tripartite guideline. Guidance on S2(R1) genotoxicity testing and data interpretation for pharmaceuticals intended for human use.
OECD. Test No. 487: In Vitro Mammalian Cell Micronucleus Test, OECD Guidelines for the testing of chemicals, Section 4. OECD Publishing, Paris; 2006. DOI: https://doi.org/10.1787/9789264264861-en.
Hamel A, Roy M, Proudlock R. The Bacterial Reverse Mutation Test. Chapter 4. Genetic toxicology testing, a laboratory manual. 2016;79-138.
Thompson C, Morley P, Kirkland D, Proudlock R. Modified bacterial mutation test procedures for evaluation of peptides and amino acid-containing material. Mutagenesis. 2005;20(5):345–350.
Marlow Foods Ltd. GRAS Notification for Mycoprotein; 2001.
Available: http://wayback.archive-it.org/799 3/20171031053437/https://www.fda.gov/downloads/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/UCM266876.pdf
Abstract View: 68 times
PDF Download: 28 times